<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230104057049N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-01-18</date_registration>
      <primary_sponsor>Bandare-abbas University of Medical Sciences</primary_sponsor>
      <public_title>Comparing the effects of aromatherapy with rosemary essential oil and lavender essential oil on the anxiety of type 2 diabetic patients with recent diagnosis</public_title>
      <acronym></acronym>
      <scientific_title>Comparing the effects of aromatherapy with rosemary essential oil and lavender essential oil on the anxiety of type 2 diabetic patients with recent diagnosis</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-01-08</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>45</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/67920</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Used, Assignment: Crossover, Purpose: Supportive, Other design features: Non-probability sampling was done based on the entry and exit criteria of the study, then they were randomly assigned into 3 groups: aromatherapy with rosemary essential oil, aromatherapy with lavender essential oil, and control. After receiving the code of ethics and consent form. First, the patients are asked to complete the demographic information questionnaire, which includes: age, sex, marital status, occupation, history of anxiety disorder and type of diabetes, as well as the Spielberger anxiety questionnaire, as well as the working methods for the intervention groups in each session. It is explained. Therefore, people in the group of rosemary essential oil inhalation will get even numbers and people in the lavender inhalation group will get odd numbers, Randomization description: The available non-random sampling method is used to select the sample people. In this way, diabetic patients who visit the Hormoz Clinic of Shahid Mohammadi Bandar Abbas Hospital in the period of October 1401, taking into account the criteria for entering the study and completing the patient consent form by the patient or his companion according to the random block method, taking into account Taking the 6 blocks whose extracted codes are given in Table 1, the sample subjects with the same volume are assigned to one of the groups of "mohammady inhalation", "lavender inhalation" and "control group".
Table (1): Random sequence generated with 6 blocks in Maine Randomization software, Blinding description: This study will be one-sided blind. In this study, in order to prevent the creation of distortion caused by the intervention of aroma therapy in the test and control group and for the purpose of research, the statistician who performs the data analysis is blinded.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Anxiety in diabetic patients.</hc_freetext>
      <i_freetext>Intervention 1: This study is cross-sectional in three groups, where each group is conducted in two stages as an intervention and one stage as a control group. The intervention in the first group is as follows: First stage: Inhalation therapy with 10% rosemary essential oil. two drops on the pad) is done at a distance of 20 cm from the patient's nose for 20 minutes and before and immediately after the end of the post test. (wash out period) and then the second stage is performed for the first group. The second stage: therapeutic inhalation with 10% lavender essential oil (two drops on a pad) is performed at a distance of 20 cm from the patient's nose for 20 minutes. And before and immediately after the end of the intervention, the post test is done. After the second stage, in order to clean the effect of the second intervention, we have a one-week wash out period, and then the third stage is done for the first group. The third stage: At this stage, the first group becomes the control group. Inhalation therapy with odorless oil (two drops on a pad) is performed at a distance of 20 cm from the patient's nose for 20 minutes. After the completion of the intervention, the post test is done. Intervention 2: The intervention in the second group is as follows: First stage: therapeutic inhalation with 10% lavender essential oil (two drops on a pad) at a distance of 20 cm from the patient's nose for 20 minutes and before and immediately after the end of the post-test intervention After the first stage, in order to clean the effect of the first intervention, we have a wash out period, and then the second stage is done for the second group. Second stage: In this stage, the first group is controlled. come Inhalation therapy with odorless oil (two drops on the pad) is performed at a distance of 20 cm from the patient's nose for 20 minutes, and before and immediately after the end of the post-test intervention. After the second stage, in order to clean The effect of the second intervention is a one-week wash out period, and then the third stage is performed for the second group. The patient's nose is done for 20 minutes and the post-test is done before and immediately after the end of the intervention. Intervention 3: Intervention group: The intervention in the third group is as follows: First stage: In this stage, the third group becomes the control. Therapeutic inhalation with odorless oil (two drops on the pad) is performed at a distance of 20 cm from the patient's nose for 20 minutes. and before and immediately after the end of the intervention, the post test is done. After the first stage, in order to clean the effect of the first intervention, we have a wash out period, and then the second stage is done for the third group. The second stage : Inhalation therapy with 10% rosemary essential oil (two drops on a pad) is performed at a distance of 20 cm from the patient's nose for 20 minutes, and a post-test is performed before and immediately after the end of the intervention. After the second stage In order to clean the effect of the second intervention, we have a wash out period of one week, and then the third stage is performed for the third group. A meter is taken from the patient's nose for 20 minutes and a post-test is performed before and immediately after the end of the intervention.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is Due to confidentiality and keeping secrets</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mohammad Hossein Taklif</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Bandar Abbas, Shahid Chamran Boulevard, Hormozgan University of Medical Sciences and Health Services</address>
        <city>Bandar Abbas</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1388579166</zip>
        <telephone>+98 76 3333 3280</telephone>
        <email>info@hums.ac.ir</email>
        <affiliation>Bandare-abbas University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mohammad Hossin Taklif</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Bandar Abbas, Shahid Chamran Boulevard, Hormozgan University of Medical Sciences and Health Services</address>
        <city>Bandafr Abbas</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1388579166</zip>
        <telephone>+98 76 3333 3280</telephone>
        <email>info@hums.ac.ir</email>
        <affiliation>Bandare-abbas University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Having a medical record with confirmed diabetes
Diagnosing the patient's diabetes in the last three months
Having moderate to severe anxiety
The patient is in the age range of 18 to 65 years
Having the physical and mental ability to answer questions
Aware of time, place and person</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Allergy to scented plants
The patient suffers from mental and nervous problems
Having a history of allergies and respiratory disease
Impaired alertness, olfactory disturbances, dissatisfaction after inhalation
Hemodynamic instability during intervention (such as symptoms of anaphylactic shock, severe fluctuations in blood pressure, blood sugar, and any severe disorder and the need for immediate intervention in vital signs)
Decreased level of consciousness during intervention
Participant's unwillingness to continue participating in the study and death
Having chronic diabetic complications such as kidney failure, heart failure, visual impairment and neuropathy</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>F15.280</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other stimulant dependence with stimulant-induced anxiety disorder</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>This study is cross-sectional in three groups, where each group is conducted in two stages as an intervention and one stage as a control group. The intervention in the first group is as follows: First stage: Inhalation therapy with 10% rosemary essential oil. two drops on the pad) is done at a distance of 20 cm from the patient's nose for 20 minutes and before and immediately after the end of the post test. (wash out period) and then the second stage is performed for the first group. The second stage: therapeutic inhalation with 10% lavender essential oil (two drops on a pad) is performed at a distance of 20 cm from the patient's nose for 20 minutes. And before and immediately after the end of the intervention, the post test is done. After the second stage, in order to clean the effect of the second intervention, we have a one-week wash out period, and then the third stage is done for the first group. The third stage: At this stage, the first group becomes the control group. Inhalation therapy with odorless oil (two drops on a pad) is performed at a distance of 20 cm from the patient's nose for 20 minutes. After the completion of the intervention, the post test is done.</i_keyword>
      <i_keyword>The intervention in the second group is as follows: First stage: therapeutic inhalation with 10% lavender essential oil (two drops on a pad) at a distance of 20 cm from the patient's nose for 20 minutes and before and immediately after the end of the post-test intervention After the first stage, in order to clean the effect of the first intervention, we have a wash out period, and then the second stage is done for the second group. Second stage: In this stage, the first group is controlled. come Inhalation therapy with odorless oil (two drops on the pad) is performed at a distance of 20 cm from the patient's nose for 20 minutes, and before and immediately after the end of the post-test intervention. After the second stage, in order to clean The effect of the second intervention is a one-week wash out period, and then the third stage is performed for the second group. The patient's nose is done for 20 minutes and the post-test is done before and immediately after the end of the intervention</i_keyword>
      <i_keyword>Intervention group: The intervention in the third group is as follows: First stage: In this stage, the third group becomes the control. Therapeutic inhalation with odorless oil (two drops on the pad) is performed at a distance of 20 cm from the patient's nose for 20 minutes. and before and immediately after the end of the intervention, the post test is done. After the first stage, in order to clean the effect of the first intervention, we have a wash out period, and then the second stage is done for the third group. The second stage : Inhalation therapy with 10% rosemary essential oil (two drops on a pad) is performed at a distance of 20 cm from the patient's nose for 20 minutes, and a post-test is performed before and immediately after the end of the intervention. After the second stage In order to clean the effect of the second intervention, we have a wash out period of one week, and then the third stage is performed for the third group. A meter is taken from the patient's nose for 20 minutes and a post-test is performed before and immediately after the end of the intervention.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Overt and hidden anxiety scores according to Spielberger's standard questionnaire. Timepoint: After filling in the demographic questionnaire and before the aromatherapy as a pre-test and at the end of 20 minutes of aromatherapy as a post-test, anxiety is measured by the Spielberger questionnaire. Method of measurement: Spielberger questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Bandare-abbas University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-12-04</approval_date>
        <contact_name>Research Ethics Committee of Hormozgan University of Medical Sciences</contact_name>
        <contact_address>End of Imam Hossein Boulevard - Hormozgan University of Medical Sciences Bandar Abbas Hormozgan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
